Mostrar el registro sencillo del ítem

Aspectos farmacogeneticos del mtx, en un grupo de pacientes colombianos con artritis reumatoide.

dc.contributor.advisorSantos, Pedro
dc.contributor.advisorBriceño Balcázar, Ignacio
dc.contributor.authorSaldarriaga Cardeno, Eugenia Lucia
dc.contributor.authorOspina, María José
dc.date.accessioned2019-02-11T16:53:17Z
dc.date.available2019-02-11T16:53:17Z
dc.date.issued2018-02-28
dc.identifier.citationSantos AM, Rueda JC, Angarita JI, Giraldo R, Forero E, Pelaez-Ballestas I, Munoz JGB, Saldarriaga EL, Ramirez J, Toro C, Londono J. Prevalence of Rheumatic Disease in an Adult Population from Colombia. A COPCORD Methodology Study. Annals of the Rheumatic Diseases 2017;76:752-3.
dc.identifier.citationAnderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O'Dell JR, Kazi S. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012;64:640-7
dc.identifier.citationSmolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
dc.identifier.citationSingh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL, Jr., Chatham WW, Paulus HE, SuarezAlmazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39
dc.identifier.citationO'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
dc.identifier.citationEmery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
dc.identifier.citationTreon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996;42:1322-9.
dc.identifier.citationVerhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998;37:612-9.
dc.identifier.citationvan Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998;27:277-92.
dc.identifier.citationGrim J, Chladek J, Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet 2003;42:139-51.
dc.identifier.citationEdno L, Bressolle F, Gomeni R, Bologna C, Sany J, Combe B. Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients. Ther Drug Monit 1996;18:128-34
dc.identifier.citationCronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739-55.
dc.identifier.citationBlits M, Jansen G, Assaraf YG, van de Wiel MA, Lems WF, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Wolbink GJ, Vosslamber S, Verweij CL. Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum 2013;65:2791-802.
dc.identifier.citationUmicevic Mirkov M, Coenen MJ. Pharmacogenetics of disease-modifying antirheumatic drugs in rheumatoid arthritis: towards personalized medicine. Pharmacogenomics 2013;14:425-44
dc.identifier.citationZhu H, Deng FY, Mo XB, Qiu YH, Lei SF. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update. Pharmacogenomics 2014;15:551-66.
dc.identifier.citationRomao VC, Lima A, Bernardes M, Canhao H, Fonseca JE. Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity? Immunol Res 2014;60:289- 310.
dc.identifier.citationBoughrara W, Benzaoui A, Aberkane M, Moghtit FZ, Dorgham S, Lardjam-Hetraf AS, Ouhaibi-Djellouli H, Teixeira EP, Boudjema A. No correlation between MTHFR c.677 C > T, MTHFR c.1298 A > C, and ABCB1 c.3435 C > T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population. Inflamm Res 2017;66:505-13
dc.identifier.citationRanganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 2008;9:439-51.
dc.identifier.citationLee YH, Bae SC. Association of the ATIC 347 C/G polymorphism with responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2016;36:1591-9.
dc.identifier.citationRestrepo LF, Giraldo R, Londoño J, Pinzón C, Cortes A, Ballesteros G, Santos AM. Farmacogenética del metotrexato en artritis reumatoide. Revisión sistemática. Revista Colombiana de Reumatologia 2016
dc.identifier.citationAletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8
dc.identifier.citationSantos AM, Saldarriaga EL, Giraldo-Bustos R, Ballesteros-Munoz JG, Rueda JC, Cuervo FM, Angarita JI, Vasquez AY, Arias-Correal S, Gonzalez CA, Santos-Moreno P, Londono J. Dickkopf 1 protein circulating levels as a possible biomarker of functional disability and chronic damage in patients with rheumatoid arthritis. Clin Rheumatol 2017
dc.identifier.citationMunoz J, Giraldo R, Santos A, Bello-Gualteros J, Rueda J, Saldarriaga E, Angarita J, Arias-CorrealS., Vasquez A, Londono J. Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis. Clin Rheumatol 2016.
dc.identifier.citationHolland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 1991;88:7276-80.
dc.identifier.citationUrano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, Akama H, Kitamura Y, Kamatani N. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002;12:183-90
dc.identifier.citationXiao H, Xu J, Zhou X, Stankovich J, Pan F, Zhang Z, Xu S, Lian L, Ding C. Associations between the genetic polymorphisms of MTHFR and outcomes of methotrexate treatment in rheumatoid arthritis. Clin Exp Rheumatol 2010;28:728-33
dc.identifier.citationRomero-Sanchez C, Gomez-Gutierrez A, Gomez PE, Casas-Gomez MC, Briceno I. C677T (RS1801133 ) MTHFR gene polymorphism frequency in a colombian population. Colomb Med (Cali) 2015;46:75-9.
dc.identifier.citationMena JP, Salazar-Paramo M, Gonzalez-Lopez L, Gamez-Nava JI, Sandoval-Ramirez L, Sanchez JD, Figuera LE, Munoz-Valle FJ, Vazquez del Mercado M, Davalos IP. Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases. Pharmacogenomics J 2011;11:287-91
dc.identifier.citationWessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, Kerstens PJ, van Zeben D, Breedveld FC, Dijkmans BA, Huizinga TW, Guchelaar HJ. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006;54:1087-95
dc.identifier.citationZajc Avramovic M, Dolzan V, Toplak N, Accetto M, Lusa L, Avcin T. Relationship Between Polymorphisms in Methotrexate Pathway Genes and Outcome of Methotrexate Treatment in a Cohort of 119 Patients with Juvenile Idiopathic Arthritis. J Rheumatol 2017;44:1216-23
dc.identifier.citationDervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, Kremer J. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74.
dc.identifier.citationGrabar PB, Rojko S, Logar D, Dolzan V. Genetic determinants of methotrexate treatment in rheumatoid arthritis patients: a study of polymorphisms in the adenosine pathway. Ann Rheum Dis 2010;69:931-2
dc.identifier.citationSalazar J, Moya P, Altes A, Diaz-Torne C, Casademont J, Cerda-Gabaroi D, Corominas H, Baiget M. Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients? Pharmacogenomics 2014;15:1079-90
dc.identifier.citationOwen SA, Lunt M, Bowes J, Hider SL, Bruce IN, Thomson W, Barton A. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J 2013;13:137-47.
dc.identifier.citationFan AZ, Yesupriya A, Chang MH, House M, Fang J, Ned R, Hayes D, Dowling NF, Mokdad AH. Gene polymorphisms in association with emerging cardiovascular risk markers in adult women. BMC Med Genet 2010;11:6.
dc.identifier.citationPalomino-Morales R, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Rodriguez L, Miranda-Filloy JA, Fernandez-Gutierrez B, Llorca J, Martin J, Gonzalez-Gay MA. A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther 2010;12:R71
dc.identifier.urihttp://hdl.handle.net/10818/34940
dc.description20 páginases_CO
dc.description.abstractEl metotrexato (MTX) como monoterapia o en combinación es el medicamento modificador de la enfermedad (FARMES) más utilizado en el tratamiento de la artritis reumatoide (AR). Cerca del 40% de los pacientes presenta falla terapéutica o toxicidad; la variabilidad genética en las enzimas involucradas en la ruta metabólica del MTX podría influenciar este fenómeno. El objetivo de este estudio es determinar la presencia de polimorfismos de nucleótido simple de su sigla en inglés (SNPs) en las enzimas implicadas en el metabolismo del MTX y su relación con la respuesta terapéutica en un grupo de pacientes colombianos con diagnóstico de artritis reumatoide.es_CO
dc.language.isospaes_CO
dc.publisherUniversidad de La Sabanaes_CO
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad de La Sabana
dc.sourceIntellectum Repositorio Universidad de La Sabana
dc.subjectMetotrexatoes_CO
dc.subjectArtritis reumatoidees_CO
dc.subjectPolimorfismo de nucleótido simplees_CO
dc.titleAspectos farmacogeneticos del mtx, en un grupo de pacientes colombianos con artritis reumatoide.es_CO
dc.typebachelorThesises_CO
dc.publisher.programEspecialización en Medicina Interna
dc.publisher.departmentFacultad de Medicina
dc.identifier.local268241
dc.identifier.localTE09541
dc.rights.accessRightsopenAccess
dc.creator.degreeEspecialista en Medicina Interna


Ficheros en el ítem

Thumbnail
Nombre:
MTX documento final PDF.pdf
Tamaño:
228.3Kb
Formato:
PDF
Descripción:
Ver documento en PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International